FDA approves ramucirumab for hepatocellular carcinoma

FDA approves ramucirumab for hepatocellular carcinoma

The recommended ramucirumab dose is 8 mg/kg administered intravenously every 2 weeks.Healthcare professionals should report all serious adverse events suspected to be associated with the use of…

8
Like
Save

Comments

Write a comment

*